Innovative treatments that will help meet physicians’ and patients’ needs

Pipeline

Product Candidate

Stage of Development

Early-Stage

Late-Stage

Submission

Commercial

VIGPODER logo1

PYR-003 vigabatrin oral solution2

PYR-001

PYR-002

1 This product is subject to REMS. For more information go to: https://vigabatrinrems.com
2 Granted Orphan Drug Designation (ODD) by the FDA. Patent pending.

For more information on our products, please contact [email protected]

Vigabatrin REMS Program Enrollment:
Visit: vigabatrinrems.com

Report an Adverse Event or Product Complaint:
Email: [email protected]
Call: (855) 406-1010

Adverse drug events may also be reported to the FDA:
Call: (800) FDA-1088
Visit: fda.gov/medwatch